EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis

Panagiotis I Georgianos, Georgios Tziatzios, Stefanos Roumeliotis, Vasilios Vaios, Vasiliki Sgouropoulou, Dimitrios G Tsalikakis, Vassilios Liakopoulos, Rajiv Agarwal

Nephrology Dialysis Transplantation · 23.01.2023 · 38 (1) · 203-211

DOI: 10.1093/ndt/gfac253 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.09.2022. Verfasst von Panagiotis I Georgianos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Hypertension. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Bayer HealthCare, Akebia Therapeutics, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) are recommended by guidelines as first-line antihypertensive therapies in the general population or in patients with earlier stages of kidney disease. However, the cardioprotective benefit of these agents among patients on dialysis remains uncertain.

Methods

We searched the MEDLINE, PubMed and Cochrane databases from inception through February 2022 to identify randomized controlled trials (RCTs) comparing the efficacy of ACEIs/ARBs relative to placebo or no add-on treatment in patients receiving dialysis. RCTs were eligible if they assessed fatal or non-fatal cardiovascular events as a primary efficacy endpoint.

Results

We identified five RCTs involving 1582 dialysis patients. Compared with placebo or no add-on treatment, the use of ACEIs/ARBs was not associated with a significantly lower risk of cardiovascular events {risk ratio [RR] 0.79 [95% confidence interval (CI) 0.57–1.11]}. Furthermore, there was no benefit in cardiovascular mortality [RR 0.82 (95% CI 0.59–1.14)] and all-cause mortality [RR 0.86 (95% CI 0.64–1.15)]. These results were consistent when the included RCTs were stratified by subgroups, including hypertension, ethnicity, sample size, duration of follow-up and quality.

Conclusion

The present meta-analysis showed that among patients on dialysis, the use of ACEIs/ARBs is not associated with a significantly lower risk of cardiovascular events and all-cause mortality as compared with placebo or no add-on treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsHypertensionHumansAngiotensin Receptor AntagonistsRenal DialysisAntihypertensive Agents

Stichwörter der Autor:innen

angiotensin receptor blockersangiotensin-converting enzyme inhibitorscardiovascular eventsdialysismortality

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive Agents

Autor:innen und Institutionen

  • Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • 2nd Department of Gastroenterology, Iatriko Athinon, Athens, Greece.
  • Department of Electrical and Computer Engineering, University of Western Macedonia, Kozani, Greece.
  • Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.

Förderung

  • Bayer HealthCare
  • Akebia Therapeutics
  • Boehringer Ingelheim
  • Eli Lilly
  • Relypsa
  • Vifor Pharma
  • Lexicon
  • Reata

Zitieren

APA

Georgianos, P. I., Tziatzios, G., Roumeliotis, S., Vaios, V., Sgouropoulou, V., Tsalikakis, D. G., Liakopoulos, V., & Agarwal, R. (2023). Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 38(1), 203-211. https://doi.org/10.1093/ndt/gfac253

Vancouver

Georgianos PI, Tziatzios G, Roumeliotis S, Vaios V, Sgouropoulou V, Tsalikakis DG, et al. Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2023;38(1):203-211. doi:10.1093/ndt/gfac253

BibTeX
@article{Georgianos2023,
  author = {Georgianos, Panagiotis I and Tziatzios, Georgios and Roumeliotis, Stefanos and Vaios, Vasilios and Sgouropoulou, Vasiliki and Tsalikakis, Dimitrios G and Liakopoulos, Vassilios and Agarwal, Rajiv},
  title = {Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {1},
  pages = {203--211},
  doi = {10.1093/ndt/gfac253}
}
Kostenlos starten →